Mural Oncology plc (MURA)
| Market Cap | 35.38M -38.3% |
| Revenue (ttm) | n/a |
| Net Income | -119.10M |
| EPS | -6.93 |
| Shares Out | 17.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,775 |
| Open | 2.030 |
| Previous Close | 2.040 |
| Day's Range | 2.030 - 2.040 |
| 52-Week Range | 0.950 - 4.740 |
| Beta | 2.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2025 |
About MURA
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncolo... [Read more]
Financial Performance
Financial StatementsNews
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of...
Mural Oncology Announces Sanction of the Scheme by the High Court
WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement betwee...
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA...
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the I...
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strateg...
Mural Oncology Announces Number of Relevant Securities in Issue
WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncolog...
FORM 8.1(a) & (b) - Mural Oncology plc
Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR...
Mural Oncology Announces Plans to Explore Strategic Alternatives
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144....
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting...
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pret...
Mural Oncology to Participate in Two Upcoming Investor Conferences
WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune ac...
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program
Mural Oncology to Present at Two Upcoming Investor Conferences
WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Mural's lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expect...